PYR-41
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
PYR-41 is the first cell permeable inhibitor of ubiquitin-activating enzyme E1, irreversibly inhibits ubiquitin-activating enzyme activity.It is a pyrazone compound that showed little or no activity on E2, E3.[1]
Unexpectedly, despite of ubiquitylation inhibition, PYR-41 also enhances total sumoylation in cells.[2]
PYR41 also blocks the downstream ubiquitination and ubiquitination-dependent protein degradation or other ubiquitination-mediated cellular activities. Besides, PYR-41 inhibits degradation of p53, a tumour suppressor and also activates the transcription activity of it.[3] PYR-41 and related pyrazones selectively kill transformed p53 expressing cells, suggesting that E1 inhibitors may be potential therapeutics in cancer.
References[edit]
- ↑ biological activity of PYR41 in selleckchem(link). {{{website}}}. selleck chemicals LLC. Sep 25, 2014.
- ↑ "Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.".Biochem Pharmacol.Aug 15, 2011;82(4)
- 341–349.doi:10.1016/j.bcp.2011.05.012.
- ↑ "Ubiquitin-activating enzyme E1 inhibitor PYR-41 attenuates angiotensin II-induced activation of dendritic cells via the IκBa/NF-κB and MKP1/ERK/STAT1 pathways.".Immunology.Jun 2014;142(2)
- 307–319.doi:10.1111/imm.12255.PMC:4008238.
 | This medical article is a stub. You can help WikiMD by expanding the page. |
